ArticleBMC complementary and alternative medicine2013
Ursolic and oleanolic acids as antimicrobial and immunomodulatory compounds for tuberculosis treatment.
Article in BMC complementary and alternative medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 2 syntheses or guidelines pooled it, 134 citations in OpenAlex.
- Medicinal Plants in the Treatment of Tuberculosis: A Systematic Review.Central nervous system agents in medicinal chemistry · 2025Pooled it
- Traditional Medicinal Plants as a Source of Antituberculosis Drugs: A System Review.BioMed research international · 2021Pooled it
- Recent advancements in drug development for pulmonary tuberculosis.Archives of microbiology · 2025Review
- Design and synthesis of natural antibacterial derivatives for ocular tuberculosis: a comprehensive review.Frontiers in pharmacology · 2025Review
- Progress of ursolic acid on the regulation of macrophage: summary and prospect.Frontiers in immunology · 2025Review
- Antimycobacterial Activity of Solid Lipid Microparticles Loaded with Ursolic Acid and Oleanolic Acid: In Vitro, In Vivo, and Toxicity Assessments.Microorganisms · 2024Article
- The In Vitro Inhibitory Activity of Pacaya Palm Rachis versus Dipeptidyl Peptidase-IV, Angiotensin-Converting Enzyme, α-Glucosidase and α-Amylase.Plants (Basel, Switzerland) · 2024Article
- Review
- The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.Frontiers in microbiology · 2024Review
- Promising Ursolic Acid as a Novel Antituberculosis Agent: Current Progress and Challenges.Drug design, development and therapy · 2024Review
- Article
- Fractionation and Characterization of Triterpenoids fromAntioxidants (Basel, Switzerland) · 2023Article
- Targeting dormant phenotype acquired mycobacteria using natural products by exploring its important targets:Frontiers in cellular and infection microbiology · 2023Article
- Secondary Metabolites with Biomedical Applications from Plants of the Sarraceniaceae Family.International journal of molecular sciences · 2022Review
- State-of-the-Art and Opportunities for Bioactive Pentacyclic Triterpenes from Native Mexican Plants.Plants (Basel, Switzerland) · 2022Review
- Article
- Modulating macrophage function to reinforce host innate resistance againstFrontiers in immunology · 2022Review
- Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicals.MedComm · 2021Review
- Efficacy of Ursolic Acid-Enriched Water-Soluble and Not Cytotoxic Nanoparticles against Enterococci.Pharmaceutics · 2021Article
- Therapeutic Potential of Ursolic Acid in Cancer and Diabetic Neuropathy Diseases.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNew alternatives for the treatment of Tuberculosis (TB) are urgently needed and medicinal plants represent a potential option. Chamaedora tepejilote and Lantana hispida are medicinal plants from Mexico and their hexanic extracts have shown antimycobacterial activity. Bioguided investigation of these extracts showed that the active compounds were ursolic acid (UA) and oleanolic acid (OA).
methodsThe activity of UA and OA against Mycobacterium tuberculosis H37Rv, four monoresistant strains, and two drug-resistant clinical isolates were determined by MABA test. The intracellular activity of UA and OA against M. tuberculosis H37Rv and a MDR clinical isolate were evaluated in a macrophage cell line. Finally, the antitubercular activity of UA and OA was tested in BALB/c mice infected with M. tuberculosis H37Rv or a MDR strain, by determining pulmonary bacilli loads, tissue damage by automated histomorphometry, and expression of IFN-γ, TNF-α, and iNOS by quantitative RT-PCR.
resultsThe in vitro assay showed that the UA/OA mixture has synergistic activity. The intracellular activity of these compounds against M. tuberculosis H37Rv and a MDR clinical isolate in a macrophage cell line showed that both compounds, alone and in combination, were active against intracellular mycobacteria even at low doses. Moreover, when both compounds were used to treat BALB/c mice with TB induced by H37Rv or MDR bacilli, a significant reduction of bacterial loads and pneumonia were observed compared to the control. Interestingly, animals treated with UA and OA showed a higher expression of IFN-γ and TNF-α in their lungs, than control animals.
conclusionUA and OA showed antimicrobial activity plus an immune-stimulatory effect that permitted the control of experimental pulmonary TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.